Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers safety and immunogenicity

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers : safety and immunogenicity

Copyright 2009 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 134(2010), 2 vom: 15. Feb., Seite 113-20
1. Verfasser: Salemi, S (VerfasserIn)
Weitere Verfasser: Picchianti-Diamanti, A, Germano, V, Donatelli, I, Di Martino, A, Facchini, M, Nisini, R, Biselli, R, Ferlito, C, Podestà, E, Cappella, A, Milanetti, F, Rossi, F, Amodeo, R, Tabacco, F, Di Rosa, R, Laganà, B, D Amelio, R
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Viral Antigens, Viral Antirheumatic Agents Immunoglobulin G Influenza Vaccines mehr... Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Infliximab B72HH48FLU Adalimumab FYS6T7F842 Etanercept OP401G7OJC
LEADER 01000naa a22002652 4500
001 NLM192212354
003 DE-627
005 20231223192552.0
007 cr uuu---uuuuu
008 231223s2010 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2009.09.014  |2 doi 
028 5 2 |a pubmed24n0641.xml 
035 |a (DE-627)NLM192212354 
035 |a (NLM)19846344 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Salemi, S  |e verfasserin  |4 aut 
245 1 0 |a Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers  |b safety and immunogenicity 
264 1 |c 2010 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.03.2010 
500 |a Date Revised 30.03.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright 2009 Elsevier Inc. All rights reserved. 
520 |a Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) alpha blockers, were immunized at least once with non-adjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNFalpha blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination 
650 4 |a Clinical Trial 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Antibodies, Viral  |2 NLM 
650 7 |a Antigens, Viral  |2 NLM 
650 7 |a Antirheumatic Agents  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Influenza Vaccines  |2 NLM 
650 7 |a Receptors, Tumor Necrosis Factor  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Infliximab  |2 NLM 
650 7 |a B72HH48FLU  |2 NLM 
650 7 |a Adalimumab  |2 NLM 
650 7 |a FYS6T7F842  |2 NLM 
650 7 |a Etanercept  |2 NLM 
650 7 |a OP401G7OJC  |2 NLM 
700 1 |a Picchianti-Diamanti, A  |e verfasserin  |4 aut 
700 1 |a Germano, V  |e verfasserin  |4 aut 
700 1 |a Donatelli, I  |e verfasserin  |4 aut 
700 1 |a Di Martino, A  |e verfasserin  |4 aut 
700 1 |a Facchini, M  |e verfasserin  |4 aut 
700 1 |a Nisini, R  |e verfasserin  |4 aut 
700 1 |a Biselli, R  |e verfasserin  |4 aut 
700 1 |a Ferlito, C  |e verfasserin  |4 aut 
700 1 |a Podestà, E  |e verfasserin  |4 aut 
700 1 |a Cappella, A  |e verfasserin  |4 aut 
700 1 |a Milanetti, F  |e verfasserin  |4 aut 
700 1 |a Rossi, F  |e verfasserin  |4 aut 
700 1 |a Amodeo, R  |e verfasserin  |4 aut 
700 1 |a Tabacco, F  |e verfasserin  |4 aut 
700 1 |a Di Rosa, R  |e verfasserin  |4 aut 
700 1 |a Laganà, B  |e verfasserin  |4 aut 
700 1 |a D Amelio, R  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 134(2010), 2 vom: 15. Feb., Seite 113-20  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:134  |g year:2010  |g number:2  |g day:15  |g month:02  |g pages:113-20 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2009.09.014  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 134  |j 2010  |e 2  |b 15  |c 02  |h 113-20